Artiva Director Granted Stock Options Worth $22K in Biotech Compensation Deal

Laura Stoppel, Director at Artiva Biotherapeutics (ARTV), received a stock option grant on June 24, 2025.

Rhea-AI Filing Summary

Laura Stoppel, Director at Artiva Biotherapeutics (ARTV), received a stock option grant on June 24, 2025. The grant consists of 13,750 options to purchase common stock at an exercise price of $1.61 per share. The options will fully vest on the earlier of June 24, 2026, or the date of the company's 2026 annual stockholder meeting.

Notable disclosure: Under an arrangement with RA Capital Management, Stoppel holds these options for the benefit of multiple funds: R.A. Capital Healthcare Fund, R.A. Capital Nexus Fund, Nexus Fund III, and a separately managed account. She must turn over any proceeds from exercise to RA Capital Management to offset advisory fees, and therefore disclaims beneficial ownership of both the options and underlying common stock.

The options have a ten-year term, expiring on June 23, 2035. This Form 4 was filed via attorney-in-fact Neha Krishnamohan on June 26, 2025.

Insider Trade Summary

Grant/Award: 13,750 shares

Grant/Award 1 txn

Insider Stoppel Laura

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	13,750	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 13,750 contracts (Direct)

Footnotes (2)

1. F1. The shares subject to the option will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting.
2. F2. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund"), the R.A. Capital Nexus Fund, L.P. (the "Nexus Fund"), the RA Capital Nexus Fund III, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did Laura Stoppel receive from ARTV on June 24, 2025?

Laura Stoppel received 13,750 stock options (Right to Buy) with an exercise price of $1.61 per share. These options were granted on June 24, 2025, and will expire on June 23, 2035.

When do Laura Stoppel's ARTV stock options vest?

The stock options will vest in full on the earlier of June 24, 2026, or the date of Artiva Biotherapeutics' 2026 annual stockholder meeting.

What is Laura Stoppel's role at ARTV?

According to the Form 4 filing, Laura Stoppel serves as a Director of Artiva Biotherapeutics, Inc. (ARTV).

Who actually benefits from Laura Stoppel's ARTV stock options?

Under an arrangement with RA Capital Management, L.P., the options benefit the R.A. Capital Healthcare Fund, L.P., the R.A. Capital Nexus Fund, L.P., the RA Capital Nexus Fund III, L.P., and a separately managed account. Any net cash or stock from exercising the options will offset advisory fees owed by these funds to RA Capital Management.

What was the total value of ARTV stock options granted to Laura Stoppel?

The Form 4 shows that Laura Stoppel received 13,750 stock options with a listed price of $0, though these options have an exercise price of $1.61 per share. The total potential value would depend on ARTV's stock price when exercised.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2025 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stoppel Laura

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$1.61	06/24/2025		A		13,750		(1)	06/23/2035	Common Stock	13,750	$0	13,750	D(2)

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting.

2. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund"), the R.A. Capital Nexus Fund, L.P. (the "Nexus Fund"), the RA Capital Nexus Fund III, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

	/s/ Neha Krishnamohan, Attorney-in-Fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.